These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 37638058)

  • 1. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
    Zhang M; Lam KP; Xu S
    Front Immunol; 2023; 14():1207276. PubMed ID: 37638058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
    Boje AS; Pekar L; Koep K; Lipinski B; Rabinovich B; Evers A; Gehlert CL; Krohn S; Xiao Y; Krah S; Zaynagetdinov R; Toleikis L; Poetzsch S; Peipp M; Zielonka S; Klausz K
    MAbs; 2024; 16(1):2315640. PubMed ID: 38372053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cells and engagers: Powerful weapons against cancer.
    Bottino C; Picant V; Vivier E; Castriconi R
    Immunol Rev; 2024 Nov; 328(1):412-421. PubMed ID: 39180430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
    Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
    Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An engineered NKp46 antibody for construction of multi-specific NK cell engagers.
    Lee RB; Maddineni S; Landry M; Diaz C; Tashfeen A; Yamada-Hunter SA; Mackall CL; Beinat C; Sunwoo JB; Cochran JR
    Protein Eng Des Sel; 2024 Jan; 37():. PubMed ID: 39163262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
    Demaria O; Gauthier L; Debroas G; Vivier E
    Eur J Immunol; 2021 Aug; 51(8):1934-1942. PubMed ID: 34145579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
    Liao B; Tumanut C; Li L; Corper A; Challa D; Chang A; Begum H; Farokhi E; Woods C; Fan X
    MAbs; 2024; 16(1):2381261. PubMed ID: 39048914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
    Colomar-Carando N; Gauthier L; Merli P; Loiacono F; Canevali P; Falco M; Galaverna F; Rossi B; Bosco F; Caratini M; Mingari MC; Locatelli F; Vivier E; Meazza R; Pende D
    Cancer Immunol Res; 2022 Mar; 10(3):291-302. PubMed ID: 35078821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.
    Gauthier L; Morel A; Anceriz N; Rossi B; Blanchard-Alvarez A; Grondin G; Trichard S; Cesari C; Sapet M; Bosco F; Rispaud-Blanc H; Guillot F; Cornen S; Roussel A; Amigues B; Habif G; Caraguel F; Arrufat S; Remark R; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E
    Cell; 2019 Jun; 177(7):1701-1713.e16. PubMed ID: 31155232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
    Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
    Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
    Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first-in-human dose for acute myeloid leukemia.
    Choi SL; Valente D; Virone-Oddos A; Mauriac C
    Clin Transl Sci; 2024 Jan; 17(1):e13689. PubMed ID: 37990450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats.
    Lipinski B; Arras P; Pekar L; Klewinghaus D; Boje AS; Krah S; Zimmermann J; Klausz K; Peipp M; Siegmund V; Evers A; Zielonka S
    Protein Sci; 2023 Mar; 32(3):e4593. PubMed ID: 36775946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.
    Klausz K; Pekar L; Boje AS; Gehlert CL; Krohn S; Gupta T; Xiao Y; Krah S; Zaynagetdinov R; Lipinski B; Toleikis L; Poetzsch S; Rabinovich B; Peipp M; Zielonka S
    J Immunol; 2022 Nov; 209(9):1724-1735. PubMed ID: 36104113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
    Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
    Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
    Tay SS; Carol H; Biro M
    Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
    Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
    Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.